Details of issuance or disposal
Monthly exercise report for the 19th Series Stock Acquisition Rights issued through a third-party allotment, with an exercise price adjustment clause
Shares delivered during the month: 2,320,000 shares (2,320,000 new shares; 0 transferred treasury shares)
The lower thin line represents the existing number of shares to which these shares will be added.
Exercise ratio subject to the exercise limit: 2.4% (2,320,000 shares delivered / 96,334,098 listed shares outstanding as of the issue and payment date)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise report for the 19th Series Stock Acquisition Rights issued through a third-party allotment, with an exercise price adjustment clause |
| Number of shares to be issued or disposed of | Shares delivered during the month: 2,320,000 shares (2,320,000 new shares; 0 transferred treasury shares) |
| Intended allottee | EVO FUND (allottee of the Series 19 stock acquisition rights) |
| Dilution Rate | Exercise ratio subject to the exercise limit: 2.4% (2,320,000 shares delivered / 96,334,098 listed shares outstanding as of the issue and payment date) |
| Total number of issued shares | As of the end of the month preceding the target month: 113,634,098 shares (including 64 treasury shares) → Not disclosed |
| Exercise price | Exercise price during the target month: ¥28.0–¥32.0. Details of the exercise price adjustment clause: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 240,000 rights; exercised during the target month: 23,200 rights; unexercised at the end of the preceding month: 67,000 rights; unexercised at the end of the target month: 43,800 rights |
| Procedures under the Corporate Code of Conduct | Reported compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | 12 June 2026: Issuance of the 19th Series Stock Acquisition Rights (with exercise price adjustment clause), with EVO FUND as the allottee (total number issued: 240,000 rights) |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status. No other reason is stated in the disclosure.